Activation of Wnt/β‐catenin pathway by inhibition of glycogen synthase kinase 3 beta (GSK3β) has been known for treatment of T2DM; however, the blood‐glucose‐lowering effects by GSK3β inhibitor are transient because its effects are confined to the liver.13 Here, GSK3B is linked to type 2 diabetes mellitus.